Cost-effectiveness analysis based on Markov model using TreeAge Pro software_Chinese Journal of Evidence-Based Medicine

Authors：

GUI Yuliang ¹ , HAN Sheng ² , WENG Hong ¹ ,  ZENG Xiantao ¹ ,  WU Bin ³

1. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University; Center for Evidence-Based and Translational Medicine, Wuhan University; Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical College, Wuhan University, Wuhan, 430071, P.R.China;
2. School of Pharmacy, Peking University; International Center for Pharmaceutical Management, Peking University, Beijing, 100191, P.R.China;
3. Department of Pharmacy, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P.R.China;

Corresponding author：

ZENG Xiantao, Email: zengxiantao1128@163.com; WU Bin, Email: withtop@126.com

Keywords：

Health economics; Pharmacoeconomics; TreeAge Pro software; Markov model; Cost-effectiveness analysis

DOI：

10.7507/1672-2531.201707008

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Health economics analysis has become increasingly important in recent years. It is essential to master the use of relevant software to conduct research in health economics. TreeAge Pro software is widely used in the healthcare decision analysis. It can carry out decision analysis, cost-effectiveness analysis, and Monte Carlo simulation. With powerful functionlity and outstanding visualization, it can build Markov disease transition models to analyze Markov processes according to disease models and accomplish decision analysis with decision trees and influence diagrams. This paper introduces cost-effectiveness analysis based on Markov model with examples and explains the main graphs.

Citation： GUI Yuliang, HAN Sheng, WENG Hong, ZENG Xiantao, WU Bin. Cost-effectiveness analysis based on Markov model using TreeAge Pro software. Chinese Journal of Evidence-Based Medicine, 2018, 18(1): 116-120. doi: 10.7507/1672-2531.201707008 Copy

1.	Myrdal G. Economic aspects in health. Chron World Health Organ, 1952, 6(7-8): 203-218.
2.	Mushkin SJ. Toward a definition of health economics. Public Health Rep, 1958, 73(9): 785-793.
3.	桂裕亮, 韩晟, 曾宪涛, 等. 卫生经济学评价研究方法学质量评价工具简介. 河南大学学报(医学版), 2017, 36(2): 129-132.
4.	Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Economics, 2001, 10(2): 179-184.
5.	Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA, 1996, 276(16): 1339-1341.
6.	Hanley N, Spash CL. Cost-benefit analysis and the environment. Aldershot: Edward Elgar, 1993: 1-278.
7.	Richardson J. Cost-utility analysis: what should be measured? Soc Sci Med, 1994, 39(1): 7-21.
8.	Treeage Software Inc. Williamstown, MA, USA. Available at: https://www.treeage.com/.
9.	孙利华. 药物经济学. 北京: 中国医药科出版社, 2010: 1-182.
10.	王倩, 金丕焕. Markov 模型在卫生经济评价的应用. 中国卫生统计, 2000, 17(2): 86-88.
11.	李鹤, 夏苏建, 马含情, 等. 达沙替尼治疗伊马替尼耐药的慢性粒细胞白血病的药物经济学评价. 中国药房, 2015, 26(2): 145-149.
12.	陈琳, 杨敏, 程国华. 尼洛替尼与达沙替尼二线治疗慢性髓系白血病的药物经济学评价. 肿瘤, 2016, 36(6): 698-704.
13.	Kulpeng W, Sompitak S, Jootar S, et al. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Therap, 2014, 36(4): 534-543.
14.	Romero M, Chávez D, De los Ríos M, et al. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica, 2014, 34(1): 48-59.
15.	Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib–a Swedish model application. Acta Oncologica, 2010, 49(6): 851-858.
16.	TreeAge Pro 2011 User's Manual. Available at: http:// files.treeage.com/treeagepro/17.1.0/20170109/TP-Manual-2017R1.pdf.

1. Myrdal G. Economic aspects in health. Chron World Health Organ, 1952, 6(7-8): 203-218.
2. Mushkin SJ. Toward a definition of health economics. Public Health Rep, 1958, 73(9): 785-793.
3. 桂裕亮, 韩晟, 曾宪涛, 等. 卫生经济学评价研究方法学质量评价工具简介. 河南大学学报(医学版), 2017, 36(2): 129-132.
4. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Economics, 2001, 10(2): 179-184.
5. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA, 1996, 276(16): 1339-1341.
6. Hanley N, Spash CL. Cost-benefit analysis and the environment. Aldershot: Edward Elgar, 1993: 1-278.
7. Richardson J. Cost-utility analysis: what should be measured? Soc Sci Med, 1994, 39(1): 7-21.
8. Treeage Software Inc. Williamstown, MA, USA. Available at: https://www.treeage.com/.
9. 孙利华. 药物经济学. 北京: 中国医药科出版社, 2010: 1-182.
10. 王倩, 金丕焕. Markov 模型在卫生经济评价的应用. 中国卫生统计, 2000, 17(2): 86-88.
11. 李鹤, 夏苏建, 马含情, 等. 达沙替尼治疗伊马替尼耐药的慢性粒细胞白血病的药物经济学评价. 中国药房, 2015, 26(2): 145-149.
12. 陈琳, 杨敏, 程国华. 尼洛替尼与达沙替尼二线治疗慢性髓系白血病的药物经济学评价. 肿瘤, 2016, 36(6): 698-704.
13. Kulpeng W, Sompitak S, Jootar S, et al. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Therap, 2014, 36(4): 534-543.
14. Romero M, Chávez D, De los Ríos M, et al. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica, 2014, 34(1): 48-59.
15. Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib–a Swedish model application. Acta Oncologica, 2010, 49(6): 851-858.
16. TreeAge Pro 2011 User's Manual. Available at: http:// files.treeage.com/treeagepro/17.1.0/20170109/TP-Manual-2017R1.pdf.

Chinese Journal of Evidence-Based Medicine

Cost-effectiveness analysis based on Markov model using TreeAge Pro software

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content